 |
市场调查报告书
商品编码
1489259
全球注意力不足过动症市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测Global Attention Deficit Hyperactivity Disorder Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
||||||
全球注意力不足过动症市场需求预计将从 2023 年的 193.2 亿美元达到 2032 年近 280 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 4.21%。
注意力不足过动症 (ADHD) 是一种神经发育疾病，其特征是过动、注意力不集中和衝动，可能会扰乱日常功能。它通常出现在儿童期，但可以持续到成年。患有多动症的人发现维持专注力、完成任务、组织活动和调节衝动具有挑战性。 ADHD 的确切原因尚不完全清楚，但据信涉及遗传、环境和神经因素。诊断通常依赖临床评估和行为评估。治疗通常包括行为疗法、药物和生活方式调整，以帮助控制症状和改善生活品质。
市场动态
注意力不足过动症 (ADHD) 市场主要是由儿童和成人 ADHD 诊断盛行率上升所推动的。对多动症症状的认识和理解的提高导致更多的人寻求医疗帮助和接受诊断。人们对心理健康问题的接受度的提高以及对过动症的耻辱感的减少也促进了市场的成长。此外，药物治疗的进步和功效增强、副作用较少的新药也推动了市场的发展。扩大针对过动症患者的行为疗法和支持服务是医疗治疗的补充，推动了市场的全面成长。此外，旨在了解过动症遗传和环境因素的研发活动不断增加，正在推动注意力不足过动症市场向前发展。然而，耻辱和误诊问题可能会挑战未来几年註意力不足过动症市场的成长。
研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球注意力不足过动症市场的各个细分市场进行了包容性评估。注意力不足过动症产业的成长和趋势为本研究提供了整体方法。
市场区隔
注意力不足过动症市场报告的这一部分提供了国家和地区层面细分市场的详细资料，从而帮助策略家确定相应产品或服务的目标人群以及即将到来的机会。
依药物类型
- 兴奋剂（安非他明、哌醋甲酯、赖右安非他命、右旋哌甲酯）
- 非兴奋剂（托莫西汀、胍法辛、可乐定等）
按人口统计
- 孩子们
- 成年人
按配销通路
- 零售药房
- 医院药房
区域分析
本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的注意力不足过动症市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。
该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。注意力不足过动症市场的主要参与者包括诺华公司、礼来公司、强生服务公司、Lupin、武田製药有限公司、Mallinckrodt Plc.、辉瑞公司、普渡製药有限公司、Aytu BioPharma Inc.（ NEOS Therapeutics Inc.)、Supernus Pharmaceuticals Inc.。进展。
如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。
目录
第一章：前言
- 报告说明
- 客观的
- 目标受众
- 独特的销售主张 (USP) 和产品
- 研究范围
- 研究方法论
- 市场研究过程
- 市场研究方法论
第 2 章：执行摘要
- 市集亮点
- 全球市场概况
第 3 章：注意力不足过动症 - 产业分析
- 简介 - 市场动态
- 市场驱动因素
- 市场限制
- 机会
- 产业动态
- 波特五力分析
- 市场吸引力分析
- 按药物类型分類的市场吸引力分析
- 按人口统计资料进行的市场吸引力分析
- 按配销通路分類的市场吸引力分析
- 市场吸引力分析：按地区
第 4 章：价值链分析
- 价值链分析
- 原料分析
- 原料清单
- 原料厂商清单
- 主要原物料价格走势
- 潜在买家名单
- 行销管道
- 直效行销
- 间接行销
- 行销通路发展趋势
第 5 章：全球注意力不足过动症市场分析：依药物类型
- 按药物类型概述
- 按药物类型的历史和预测数据分析
- 兴奋剂（安非他明、哌醋甲酯、赖右安非他命、右旋哌甲酯）
- 非兴奋剂（托莫西汀、胍法辛、可乐定等）
第 6 章：全球注意力不足过动症市场分析：按人口统计
- 按人口统计概况
- 按人口统计资料进行历史和预测资料分析
- 孩子们
- 成年人
第 7 章：全球注意力不足过动症市场分析：按分销管道
- 配销通路概述
- 按配销通路进行历史和预测资料分析
- 零售药房
- 医院药房
第 8 章：全球注意力不足过动症市场分析：按地理位置
- 区域展望
- 介绍
- 北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
- 欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
- 亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
- 拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
- 中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析
第 9 章：注意力不足过动症公司的竞争格局
- 注意力不足过动症市场竞争
- 伙伴关係/协作/协议
- 併购
- 新产品发布
- 其他发展
第 10 章：公司简介
- 顶级公司市占率分析
- 市场集中度
- Novartis AG
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Eli Lilly And Company
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Johnson & Johnson Services Inc.
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Lupin
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Takeda Pharmaceutical Company Limited
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Mallinckrodt Plc.
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Pfizer Inc.
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Purdue Pharma LP
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Aytu BioPharma Inc. (NEOS Therapeutics Inc.)
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Supernus Pharmaceuticals Inc
- 公司简介
- 公司收入
- 产品
- 最近的发展
註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内
The global demand for Attention Deficit Hyperactivity Disorder Market is presumed to reach the market size of nearly USD 28 Billion by 2032 from USD 19.32 Billion in 2023 with a CAGR of 4.21% under the study period 2024-2032.
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition featuring symptoms of hyperactivity, inattention, and impulsivity, which can disrupt daily functioning. It commonly presents in childhood but can continue into adulthood. Individuals with ADHD find it challenging to sustain attention, accomplish tasks, organize activities, and regulate impulses. The exact cause of ADHD is not wholly understood but is believed to involve genetic, environmental, and neurological factors. Diagnosis typically relies on clinical evaluation and behavioral assessments. Treatment often includes behavioral therapy, medication, and lifestyle adjustments to help manage symptoms and improve quality of life.
MARKET DYNAMICS
The attention deficit hyperactivity disorder (ADHD) market is primarily driven by the rising prevalence of ADHD diagnoses among children and adults. Increased awareness and better understanding of ADHD symptoms have led to more individuals seeking medical help and receiving diagnoses. The spurring acceptance of mental health issues and the reduction of stigma surrounding ADHD have also contributed to market growth. Furthermore, advancements in pharmaceutical treatments and new medications with enhanced efficacy and fewer side effects have boosted the market. Expanding behavioral therapies and support services for ADHD patients complements medical treatments, driving comprehensive market growth. Additionally, increasing research & development activities aimed at understanding the genetic and environmental factors of ADHD are propelling the attention deficit hyperactivity disorder market forward. However, stigma and misdiagnosis issues may challenge the attention deficit hyperactivity disorder market growth in the coming years.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Attention Deficit Hyperactivity Disorder. The growth and trends of Attention Deficit Hyperactivity Disorder industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Attention Deficit Hyperactivity Disorder market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Drug Type
- Stimulants (Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate)
- Non-stimulants (Atomoxetine, Guanfacine, Clonidine, Others)
By Demographics
- Children
- Adults
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
REGIONAL ANALYSIS
This section covers the regional outlook, which accentuates current and future demand for the Attention Deficit Hyperactivity Disorder market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Attention Deficit Hyperactivity Disorder market include Novartis AG, Eli Lilly And Company, Johnson & Johnson Services Inc., Lupin, Takeda Pharmaceutical Company Limited, Mallinckrodt Plc., Pfizer Inc., Purdue Pharma L.P., Aytu BioPharma Inc. (NEOS Therapeutics Inc.), Supernus Pharmaceuticals Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1. PREFACE
- 1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology
2. EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3. ATTENTION DEFICIT HYPERACTIVITY DISORDER - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Demographics
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend
5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET ANALYSIS BY DRUG TYPE
- 5.1. Overview By Drug Type
- 5.2. Historical and Forecast Data Analysis By Drug Type
- 5.3. Stimulants (Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate) Historic and Forecast Sales By Regions
- 5.4. Non-stimulants (Atomoxetine, Guanfacine, Clonidine, Others) Historic and Forecast Sales By Regions
6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET ANALYSIS BY DEMOGRAPHICS
- 6.1. Overview By Demographics
- 6.2. Historical and Forecast Data Analysis By Demographics
- 6.3. Children Historic and Forecast Sales By Regions
- 6.4. Adults Historic and Forecast Sales By Regions
7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET ANALYSIS BY DISTRIBUTION CHANNEL
- 7.1. Overview By Distribution Channel
- 7.2. Historical and Forecast Data Analysis By Distribution Channel
- 7.3. Retail Pharmacy Historic and Forecast Sales By Regions
- 7.4. Hospital Pharmacy Historic and Forecast Sales By Regions
8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET ANALYSIS BY GEOGRAPHY
- 8.1. Regional Outlook
- 8.2. Introduction
- 8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
- 8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
- 8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
- 8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
- 8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis
9. COMPETITIVE LANDSCAPE OF THE ATTENTION DEFICIT HYPERACTIVITY DISORDER COMPANIES
- 9.1. Attention Deficit Hyperactivity Disorder Market Competition
- 9.2. Partnership/Collaboration/Agreement
- 9.3. Merger And Acquisitions
- 9.4. New Product Launch
- 9.5. Other Developments
10. COMPANY PROFILES OF ATTENTION DEFICIT HYPERACTIVITY DISORDER INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Market Concentration Rate
- 10.3. Novartis AG
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
- 10.4. Eli Lilly And Company
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
- 10.5. Johnson & Johnson Services Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
- 10.6. Lupin
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
- 10.7. Takeda Pharmaceutical Company Limited
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
- 10.8. Mallinckrodt Plc.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
- 10.9. Pfizer Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
- 10.10. Purdue Pharma L.P.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
- 10.11. Aytu BioPharma Inc. (NEOS Therapeutics Inc.)
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
- 10.12. Supernus Pharmaceuticals Inc
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies
LIST OF TABLES
- Market Snapshot
- Drivers: Impact Analysis
- Restraints: Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- Analysis By Drug Type (USD MN)
- Stimulants (Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate) Market Sales By Geography (USD MN)
- Non-stimulants (Atomoxetine, Guanfacine, Clonidine, Others) Market Sales By Geography (USD MN)
- Analysis By Demographics (USD MN)
- Children Market Sales By Geography (USD MN)
- Adults Market Sales By Geography (USD MN)
- Analysis By Distribution Channel (USD MN)
- Retail Pharmacy Market Sales By Geography (USD MN)
- Hospital Pharmacy Market Sales By Geography (USD MN)
- Global Attention Deficit Hyperactivity Disorder Market Sales By Geography (USD MN)
- North America Market Analysis (USD MN)
- United States Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate By Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- South East Asia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisition
LIST OF FIGURES
- Research Scope of Attention Deficit Hyperactivity Disorder Report
- Market Research Process
- Market Research Methodology
- Global Attention Deficit Hyperactivity Disorder Market Size, By Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis By Drug Type
- Market Attractiveness Analysis By Demographics
- Market Attractiveness Analysis By Distribution Channel
- Market Attractiveness Analysis By Region
- Value Chain Analysis
- Global Market Analysis By Drug Type (USD MN)
- Stimulants (Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate) Market Sales By Geography (USD MN)
- Non-stimulants (Atomoxetine, Guanfacine, Clonidine, Others) Market Sales By Geography (USD MN)
- Global Market Analysis By Demographics (USD MN)
- Children Market Sales By Geography (USD MN)
- Adults Market Sales By Geography (USD MN)
- Global Market Analysis By Distribution Channel (USD MN)
- Retail Pharmacy Market Sales By Geography (USD MN)
- Hospital Pharmacy Market Sales By Geography (USD MN)
- Global Market Sales (USD MN)
- North America Market Sales (USD MN)
- Europe Market Sales (USD MN)
- Asia Pacific Market Sales (USD MN)
- Latin America Market Sales (USD MN)
- Middle East & Africa Market Sales (USD MN)
- Recent Development in Industry
- Top Company Market Share Analysis
Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
注意力不足过动症市场机会、成长动力、产业趋势分析与预测 2024 - 2032
注意力不足过动症市场：按治疗方法、患者类型和应用分类 - 全球预测 2025-2030
全球 ADHD（注意力不足过动症）市场：依治疗类型、年龄层、ADHD 亚型、地区、范围和预测美国过动症和自闭症诊所市场规模、份额、趋势分析报告：按症状、服务、国家、细分市场预测，2024-2030 年
ADHD市场、占有率、规模、趋势、行业分析报告：依药物类型、通路、人口统计、地区、细分市场预测，2024-2032年ADHD（注意力不足过动症）市场规模、份额、趋势分析报告：按药物类型、人口统计、分销管道、地区、细分市场预测，2024-2030 年
注意力不足过动症治疗市场（药物类型：兴奋剂和非兴奋剂；年龄：儿童（2至17岁）和成人）-全球产业分析、规模、份额、成长、趋势和预测，2024年- 2034注意力不足过动症市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按药物类型、配销通路、地区和竞争细分